logo

For the Inventor, By the Inventor

Seattle, WA, United States of America

David M Hollenback

This inventor holds 7 USPTO granted patents and 1 published patent application. Top assignee: Cell Therapeutics, Inc.. Active years: 2001-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David M Hollenback. Retrieved from https://idiyas.com/inventor/david-m-hollenback

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 14.3

Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 55(Granted Patents)


Company Filing History:

goldMedal7 out of 103 
 
Cell Therapeutics, Inc.
 patents

Years Active: 2001-2009

Loading Chart...
7 patents (USPTO):Explore Patents
1. 7608620 - LPAAT-β inhibitors and uses thereof (2009-10-27),
2. 7199238 - LPAAT-β inhibitors and uses thereof (2007-04-03),
3. 7064125 - LPAAT-β inhibitors and uses thereof (2006-06-20),
4. 7052891 - Human lysophoshatidic acid acyltransferase gamma-1 polypeptide (2006-05-30),
5. 7045327 - Human lysophosphatidic acid acyltransferase gamma-2 polypeptide (2006-05-16),
6. 6670143 - Method of screening compounds that inhibit lysophosphatidic acid acyltransferase (2003-12-30),
7. 6300487 - Mammalian lysophosphatidic acid acyltransferase (2001-10-09),

Title: The Innovative Contributions of David M Hollenback

Introduction

David M Hollenback is a notable inventor based in Seattle, WA. He has made significant contributions to the field of biotechnology, particularly in cancer treatment. With a total of 7 patents to his name, Hollenback's work has the potential to impact medical science profoundly.

Latest Patents

One of Hollenback's latest patents is focused on LPAAT-β inhibitors and their uses. This invention relates to triazines and their application in inhibiting lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention also outlines methods for treating cancer using these triazines, as well as methods for screening LPAAT-β activity. This innovative approach showcases Hollenback's commitment to advancing cancer therapies.

Career Highlights

Throughout his career, Hollenback has worked with various companies, including Cell Therapeutics, Inc. and Cell Therapeutics, Inc. His experience in these organizations has allowed him to develop and refine his inventions, contributing to the advancement of medical technologies.

Collaborations

Hollenback has collaborated with notable individuals in his field, including David W Leung and Daniel Adourel. These partnerships have likely enriched his work and expanded the scope of his innovations.

Conclusion

David M Hollenback's contributions to biotechnology and cancer treatment through his patents and collaborations highlight his role as a significant inventor in the field. His innovative work continues to pave the way for advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…